The persisting challenge of selective and specific proteasome inhibition

Journal of Peptide Science

Volumn 15, Issue 2, 2009, Pages 58-66

  Groll, Michael ^a   Huber, Robert ^b,c,d   Moroder, Luis ^b  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b MAX PLANCK INSTITUTE OF BIOCHEMISTRY   (Germany)

^c UNIVERSITY OF ESSEN MEDICAL SCHOOL   (Germany)

^d CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

Crystallographic analysis; Inhibitors; Polyvalency; Proteasome; Synthetic and natural products

Indexed keywords

ALDEHYDE DERIVATIVE; AMINO ACID DERIVATIVE; ARGYRIN A; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; BETA LACTONE DERIVATIVE; BIA 1A; BIA 2A; BORTEZOMIB; CALPASTATIN; EPOXOMICIN; FELLUTAMIDE B; GLIDOBACTIN A; HEPTAKIS [6 (SUCCINYLPHENYLALANINEAMIDE)AMIDO 6 DEOXY]BETA CYCLODEXTRIN; HOMOBELACTOSIN C; LACTACYSTIN BETA LACTONE; NATURAL PRODUCT; OCTAPEPTIDE; PR 171; PROTEASOME; PROTEASOME INHIBITOR; SALINOSPORAMIDE A; SYRBACTIN DERIVATIVE; SYRINGOLIN A; TMC 95; TMC 95A; TRIPEPTIDE DERIVATIVE; UNCLASSIFIED DRUG; VINYL SULFONE DERIVATIVE; BORONIC ACID DERIVATIVE; PROTEINASE INHIBITOR; PYRAZINE DERIVATIVE;

BINDING AFFINITY; CLINICAL TRIAL; DRUG CYTOTOXICITY; DRUG DESIGN; DRUG EFFECT; DRUG MECHANISM; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG RESEARCH; DRUG STABILITY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME STRUCTURE; HUMAN; MALIGNANT NEOPLASTIC DISEASE; MULTIPLE MYELOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN TARGETING; REVIEW; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS; CHEMICAL STRUCTURE; CHEMISTRY; DRUG ANTAGONISM; METABOLISM; PROTEIN CONFORMATION;

BORONIC ACIDS; CATALYTIC DOMAIN; DRUG DESIGN; HUMANS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; MULTIPLE MYELOMA; PROTEASE INHIBITORS; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN CONFORMATION; PYRAZINES;

EID: 61449206184     PISSN: 10752617     EISSN: 10991387     Source Type: Journal    
DOI: 10.1002/psc.1107     Document Type: Review

References (65)

1. Hershko A, Ciechanover A. The ubiquitin system. Annu. Rev. Biochem. 1998; 67: 425-479.
2. Groll M, Clausen T. Molecular shredders: how proteasomes fulfill their role. Curr. Opin. Struct. Biol. 2003; 13: 665-673.
3. Groll M, Bochtler M, Brandstetter H, Clausen T, Huber R. Molecular machines for protein degradation. Chem Biochem 2005; 6: 222-256.
4. Adams J. The development of proteasome inhibitors as anticancer drugs. Cancer Cell 2004; 5: 417-421.
5. Adams J. The proteasome: a suitable antineoplastic target. Nature Rev. Cancer 2004; 4: 349-360.
6. Mitsiades CS, Mitsiades N, Hideshima T, Richardson PG, Anderson KC. Proteasome inhibitors as therapeutics. In Essays in Biochemistry: The Ubiquitin-Proteasome System, Vol. 41, Mayer RJ, Layfield R (eds.). Portland Press: London, 2005; 205-218.
7. Goldberg AL. Functions of the proteasome: from protein degradation and immune surveillance to cancer therapy. Biochem. Soc. Trans. 2007; 35: 12-17.
8. Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T, Harousseau JL, Ben-Yehuda D, Lonial S, Goldschmidt H, Reece D, San-Miguel JF, Blade J, Boccadoro M, Cavenagh J, Dalton WS, Boral AL, Esseltine DL, Porter JB, Schenkein D, Anderson KC. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N. Engl. J. Med. 2005; 352: 2487-2498.
9. Orlowski RZ, Kuhn DJ. Proteasome inhibitors in cancer therapy: lessons from the first decade. Clin. Cancer Res. 2008; 14: 1649-1657.
10. Argyriou AA, Iconomou G, Kalofonos HP. Bortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature. Blood 2008; 112: 1593-1599.
11. Hegerl R, Pfeifer G, Puhler G, Dahlmann B, Baumeister W. The 3-dimensional structure of proteasomes from Thermoplasma-Acidophilum as determined by electron-microscopy using random conical tilting. FEBS Lett. 1991; 283: 117-121.
12. L öwe J, Stock D, Jap R, Zwickl P, Baumeister W, Huber R. Crystal structure of the 20S proteasome from the archaeon T-Acidophilum at 3.4 Å resolution. Science 1995; 268: 533-539.
13. Groll M, Ditzel L, Löwe J, Stock D, Bochtler M, Bartunik HD, Huber R. Structure of 20S proteasome from yeast at 2.4 Å resolution. Nature 1997; 386: 463-471.
14. Borissenko L, Groll M. 20S proteasome and its inhibitors: crystallographic knowledge for drug development. Chem. Rev. 2007; 107: 687-717.
15. Reece DE, Leitch HA, Atkins H, Voralia M, Canning LA, Le Blanc R, Belch AR, White D, Kovacs KJ. Treatment of relapsed and refractory myeloma. Leuk. Lymphoma 2008; 49: 1470-14855.
16. Loidl G, Groll M, Musiol H-J, Ditzel L, Huber R, Moroder L. Bifunctional inhibitors of the trypsin-like activity of eukaryotic proteasomes. Chem. Biol. 1999; 6: 197-204.
17. Groll M, Brandstetter H, Bartunik H, Bourenkow G, Huber R. Investigations on the maturation and regulation of archaebacterial proteasomes. J. Mol. Biol. 2003; 327: 75-83.
18. Braun HA, Umbreen S, Groll M, Kuckelkorn U, Mlynarczuk I, Wigand ME, Drung I, Kloetzel PM, Schmidt B. Tripeptide mimetics inhibit the 20S proteasome by covalent bonding to the active threonines. J. Biol. Chem. 2005; 280: 28394-28401.
19. Jager S, Groll M, Huber R, Wolf DH, Heinemeyer W. Proteasome β-type subunits: unequal roles of propeptides in core particle maturation and a hierarchy of active site function. J. Mol. Biol. 1999; 291: 997-1013.
20. Groll M, Heinemeyer W, Jager S, Ullrich T, Bochtler M, Wolf DH, Huber R. The catalytic sites of 20S proteasomes and their role in subunit maturation: a mutational and crystallographic study. Proc. Natl. Acad. Sci. U.S.A. 1999; 96: 10976-10983.
21. Vinitsky A, Michaud C, Powers JC, Orlowski M. Inhibition of the chymotrypsin-like activity of the pituitary multicatalytic proteinase complex. Biochemistry 1992; 31: 9421-9428.
22. Shaw E. Cysteinyl proteinases and their selective inactivation. Adv. Enzymol. Relat. Areas Mol. Biol. 1990; 63: 271-347.
23. Hines J, Groll M, Fahnestock M, Crews CM. Proteasome inhibition by fellutamide B induces nerve growth factor synthesis. Chem. Biol. 2008; 15: 501-512.
24. Palombella VJ, Rando OJ, Goldberg AL, Maniatis T. The ubiquitin-proteasome pathway is required for processing the NF-kappa B1 precursor protein and the activation of NF-κB. Cell 1994; 78:773-785.
25. Bogyo M, Shin S, McMaster JS, Ploegh HL. Substrate binding and sequence preference of the proteasome revealed by active-site directed affinity probes. Chem. Biol. 1998; 5: 307-320.
26. Groll M, Nazif T, Huber R, Bogyo M. Probing structural determinants distal to the site of hydrolysis that control substrate specificity of the 20S proteasome. Chem. Biol. 2002; 9: 655-662.
27. Nazif T, Bogyo M. Global analysis of proteasomal substrate specificity using positional-scanning libraries of covalent inhibitors. Proc. Natl. Acad. Sci. U.S.A. 2001; 98: 2967-2972.
28. Adams J, Behnke M, Chen SW, Cruickshank AA, Dick LR, Grenier L, Klunder JM, Ma YT, Plamondon L, Stein RL. Potent and selective inhibitors of the proteasome: dipeptidyl boronic acids. Bioorg. Med. Chem. Lett. 1998; 8: 333-338.
29. Groll M, Berkers CR, Ploegh HL, Ovaa H. Crystal structure of the boronic acid-based proteasome inhibitor bortezomib in complex with the yeast 20S proteasome. Structure 2006; 14: 451-456.
30. Fenteany G, Standaert RF, Lane WS, Choi S, Corey EJ, Schreiber SL. Inhibition of proteasome activities and subunit-specific aminoterminal threonine modification by lactacystin. Science 1995; 268: 726-731.
31. Groll M, Huber R, Potts BC. Crystal structures of salinosporamide A (NPI-0052) and B (NPI-0047) in complex with the 20S proteasome reveal important consequences of β-lactone ring opening and a mechanism for irreversible binding. J. Am. Chem. Soc. 2006; 128: 5136-5141.
32. Groll M, Larionov OV, Huber R, de Meijere A. Inhibitor-binding mode of homobelactosin C to proteasomes: new insights into class I MHC ligand generation. Proc. Natl. Acad. Sci. U.S.A. 2006; 103: 4576-4579.
33. Meng LH, Mohan R, Kwok BHB, Elofsson M, Sin N, Crews CM. Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo antiinflammatory activity. Proc. Natl. Acad. Sci. U.S.A. 1999; 96: 10403-10408.
34. Groll M, Kim KB, Kairies N, Huber R, Crews CM. Crystal structure of epoxomicin:20S proteasome reveals a molecular basis for selectivity of α′, β′-epoxyketone proteasome inhibitors. J. Am. Chem. Soc. 2000; 122: 1237-1238.
35. Groll M, Schellenberg B, Bachmann AS, Archer CR, Huber R, Powell TK, Lindow S, Kaiser M, Dudler R. A plant pathogen virulence factor inhibits the eukaryotic proteasome by a novel mechanism. Nature 2008; 452: 755-758.
36. Groll M, Huber R. Inhibitors of the eukaryotic 20S proteasome core particle: a structural approach. Biochim. Biophys. Acta 2004; 1695: 33-44.
37. Borissenko L, Groll M. Diversity of proteasomal missions: fine tuning of the immune response. Biol. Chem. 2007; 388: 947-955.
38. Demo SD, Kirk CJ, Aujay MA, Buchholz TJ, Dajee M, Ho MN, Jiang J, Laidig GJ, Lewis ER, Parlati F, Shenk KD, Smyth MS, Sun CM, Vallone MK, Woo TM, Molineaux CJ, Bennett MK. Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome. Cancer Res. 2007; 67: 6383-6391.
39. Feling RH, Buchanan GO, Mincer TJ, Kauffman CA, Jensen PR, Fenical W. Salinosporamide A: a highly cytotoxic proteasome inhibitor from a novel microbial source, a marine bacterium of the new genus Salinospora. Angew. Chem., Int. Ed. Engl. 2003; 42: 355-357.
40. Ahn KS, Sethi G, Chao TH, Neuteboom STC, Chaturvedi MM, Palladino MA, Younes A, Aggarwal BB. Salinosporamide A (NPI-0052) potentiates apoptosis, suppresses osteoclastogenesis, and inhibits invasion through down-modulation of NF-κB-regulated gene products. Blood 2007; 110: 2286-2295.
41. Miller CP, Ban K, Dujka ME, McConkey DJ, Munsell M, Palladino M, Chandra J. NPI-0052, a novel proteasome inhibitor, induces caspase-8 and ROS-dependent apoptosis alone and in combination with HDAC inhibitors in leukemia cells. Blood 2007; 110: 267-277.
42. Imajoh-Ohmi S, Kawaguchi T, Sugiyama S, Tanaka K, Omura S, Kikuchi H. Lactacystin, a specific inhibitor of the proteasome, induces apoptosis in human monoblast U937 cells. Biochem. Biophys. Res. Commun. 1995; 217: 1070-1077.
43. Shinohara K, Tomioka M, Nakano H, Tone S, Ito H, Kawashima S. Apoptosis induction resulting from proteasome inhibition. Biochem. J. 1996; 317: 385-388.
44. Hideshima T, Richardson P, Chauhan D, Palombella VJ, Elliott PJ, Adams J, Anderson KC. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res. 2001; 61: 3071-3076.
45. Koguchi Y, Kohno J, Nishio M, Takahashi K, Okuda T, Ohnuki T, Komatsubara S. TMC-95A, B, C, and D, novel proteasome inhibitors produced by Apiospora montagnei Sacc. TC 1093 - Taxonomy, production, isolation, and biological activities. J. Antibiot. 2000; 53: 105-109.
46. Kohno J, Koguchi Y, Niskio M, Nakao K, Kuroda M, Shimizu R, Ohnuki T, Komatsubara S. Structures of TMC-95A-D: novel proteasome inhibitors from Apiospora montagnei Sacc. TC 1093. J. Org. Chem. 2000; 65: 990-995.
47. Groll M, Koguchi Y, Huber R, Kohno J. Crystal structure of the 20S proteasome/TMC-95A complex: a non-covalent proteasome inhibitor. J. Mol. Biol. 2001; 311: 543-548.
48. Groll M, Götz M, Kaiser M, Weyher E, Moroder L. TMC-95-based inhibitor design provides evidence for the catalytic versatility of the proteasome. Chem. Biol. 2006; 13: 607-614.
49. Kaiser M, Groll M, Renner C, Huber R, Moroder L. The core structure of TMC-95A is a promising lead for reversible proteasome inhibition. Angew. Chem., Int. Ed. Engl. 2002; 41: 780-783.
50. -. Acta Crystallogr., Sect. C-Crystal Struct. Commun. 1996; 52: 3112-3114.
51. Janetka JW, Raman P, Satyshur K, Flentke GR, Rich DH. Novel cyclic biphenyl ether peptide β-strand mimetics and HIV-protease inhibitors. J. Am. Chem. Soc. 1997; 119: 441-442.
52. Müller G, Giera H. Protein secondary structure templates derived from bioactive natural products - Combinatorial chemistry meets structure-based design. J. Comput.-Aided Mol. Des. 1998; 12: 1-6.
53. Kaiser M, Milbradt AG, Siciliano C, Assfalg-Machleidt I, Machleidt W, Groll M, Renner C, Moroder L. TMC-95A analogues with endocyclic biphenyl ethergroup as proteasome inhibitors. Chem. Biodiver. 2004; 1: 161-173.
54. Vigneron N, Stroobant V, Chapiro J, Ooms A, Degiovanni G, Morel S, van der Bruggen P, Boon T, van den Eynde BJ. An antigenic peptide produced by peptide splicing in the proteasome. Science 2004; 304: 587-590.
55. Sasse F, Steinmetz H, Schupp T, Petersen F, Memmert K, Hofmann H, Heusser C, Brinkmann V, Von Matt P, Höfle G, Reichenbach H. Argyrins, immunosuppressive cyclic peptides frommyxobacteria - I. Production, isolation, physico-chemical and biological properties. J. Antibiot. 2002; 55: 543-551.
56. Nickeleit I, Zender S, Sasse F, Geffers R, Brandes G, Sorensen I, Steinmetz H, Kubicka S, Carlomagno T, Menche D, Gutgemann I, Buer J, Gossler A, Manns MP, Kalesse M, Frank R, Malek NP. Argyrin A reveals a critical role for the tumor suppressor protein p27(kip1) in mediating antitumor activities in response to proteasome inhibition. Cancer Cell 2008; 14: 23-35.
57. Loidl G, Groll M, Musiol H-J, Huber R, Moroder L. Bivalency as a principle for proteasome inhibition. Proc. Natl. Acad. Sci. U.S.A. 1999; 96: 5418-5422.
58. Wenzel T, Baumeister W. Conformational constraints in protein degradation by the 20S proteasome. Nat. Struct. Biol. 1995; 2: 199-204.
59. Mammen M, Choi SK, Whitesides GM. Polyvalent interactions in biological systems: implications for design and use of multivalent ligands and inhibitors. Angew. Chem., Int. Ed. Engl. 1998; 37: 2755-2794.
60. Moroder L. Application of the principle of polyvalency to protease inhibition. In Modern Biopharmaceuticals - Design, Development and Optimization, Vol. 2, Knäblein J (ed.). Wiley-VCH: Weinheim, 2005; 395-417.
61. Loidl G, Musiol HJ, Groll M, Huber R, Moroder L. Synthesis of bivalent inhibitors of eukaryotic proteasomes. J. Pept. Sci. 2000; 6: 36-46.
62. Mammen M, Shakhnovich EI, Deutch JM, Whitesides GM. Estimating the entropic cost of self-assembly of multiparticle hydrogen-bonded aggregates based on the cyanuric acid-melamine lattice. J. Org. Chem. 1998; 63: 3821-3830.
63. Mammen M, Shakhnovich EI, Whitesides GM. Using a convenient, quantitative model for torsional entropy to establish qualitative trends formolecular processes that restrict conformational freedom. J. Org. Chem. 1998; 63: 3168-3175.
64. Veronese FM, Pasut G. PEGylation, successful approach for drug delivery. Drug Discov. Today 2005; 10: 1451-1458.
65. Pilkington-Miksa MA, Sarkar S, Writer MJ, Barker SE, Shamlou PA, Hart SL, Hailes HC, Tabor AB. Synthesis and bifunctional integrinbinding peptides containing PEG spacers of defined length for non-viral gene delivery. Eur. J. Org. Chem. 2008; 2900-2914.